MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

Search

Penumbra Inc

Closed

SectorHealthcare

236.18 -1.08

Overview

Share price change

24h

Current

Min

235.34

Max

239.16

Key metrics

By Trading Economics

Income

5.5M

39M

Sales

8.6M

324M

P/E

Sector Avg

232.122

39.564

Profit margin

12.101

Employees

4,500

EBITDA

131K

49M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+32.32% upside

Dividends

By Dow Jones

Next Earnings

29 lip 2025

Market Stats

By TradingEconomics

Market Cap

-1.1B

9.6B

Previous open

237.26

Previous close

236.18

News Sentiment

By Acuity

50%

50%

148 / 376 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

Penumbra Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

14 lip 2025, 22:07 UTC

Major Market Movers

Trade Desk Rises on S&P 500 Inclusion

14 lip 2025, 17:06 UTC

Major Market Movers

Crypto Assets Rally Ahead of Possible U.S. Legislation

14 lip 2025, 16:47 UTC

Acquisitions, Mergers, Takeovers

NatWest to Sell Stake in Permanent TSB

14 lip 2025, 23:46 UTC

Market Talk

Nikkei May Rise as Yen Weakens -- Market Talk

14 lip 2025, 23:38 UTC

Market Talk

Gold Edges Higher Ahead of U.S. CPI Data -- Market Talk

14 lip 2025, 23:37 UTC

Market Talk

ANZ's Institutional Earnings Likely to Weigh on Outlook -- Market Talk

14 lip 2025, 23:29 UTC

Market Talk

South32 Bull Eyes Possible Last-Minute Power Deal for Mozal -- Market Talk

14 lip 2025, 23:29 UTC

Market Talk

Global Energy Roundup: Market Talk

14 lip 2025, 23:02 UTC

Earnings

China Vanke: Additional Provision for Asset Impairment Also Among Factors Weighing on Results >000002.SZ

14 lip 2025, 23:02 UTC

Earnings

China Vanke: Weakness in Overall China Real-Estate Sector Weighed on Results >000002.SZ

14 lip 2025, 23:02 UTC

Earnings

China Vanke 1H Loss Was CNY9.85B >000002.SZ

14 lip 2025, 23:01 UTC

Earnings

China Vanke Sees 1H Loss CNY10.0B-Loss CNY12.0B >000002.SZ

14 lip 2025, 23:01 UTC

Earnings

China Vanke Expects 1H Loss to Widen >000002.SZ

14 lip 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

14 lip 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

14 lip 2025, 20:07 UTC

Market Talk

Cloud Computing Giants Will Be the Winner from Software's Loss -- Market Talk

14 lip 2025, 20:05 UTC

Market Talk

Adobe and Salesforce May Struggle to Keep Up With AI Agents -- Market Talk

14 lip 2025, 19:11 UTC

Market Talk

Oil Retreats Despite Trump Threats of Russia Sanctions -- Market Talk

14 lip 2025, 19:09 UTC

Market Talk

Gold Breaks a 3-Day Win Streak -- Market Talk

14 lip 2025, 18:59 UTC

Market Talk

Hotter Weather Outlook, LNG Flows Boost U.S. Natural Gas -- Market Talk

14 lip 2025, 18:30 UTC

Acquisitions, Mergers, Takeovers

Synopsys Buy of Ansys Gets China OK. The $35 Billion Deal Is Set to Close. -- Barrons.com

14 lip 2025, 18:25 UTC

Market Talk

Dollar Gains, Treasury Yields Lose Steam as Trump Threatens Russia -- Market Talk

14 lip 2025, 18:25 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14 lip 2025, 16:59 UTC

Market Talk

Goldman Sachs Lifts 2H25 Crude Price Views -- Market Talk

14 lip 2025, 16:53 UTC

Hot Stocks

Stocks to Watch Monday: Kenvue, Tesla, Synopsys, Robinhood -- WSJ

14 lip 2025, 16:27 UTC

Market Talk

Oil Falls as Investors Monitor U.S.-EU Trade, Trump's Russia Sanction Threats -- Market Talk

14 lip 2025, 16:20 UTC

Market Talk
Earnings

Auto & Transport Roundup: Market Talk

14 lip 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

14 lip 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

14 lip 2025, 16:12 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Waters Closer to Thermo Fisher, Danaher With Becton Dickinson Unit -- Market Talk

Peer Comparison

Price change

Penumbra Inc Forecast

Price Target

By TipRanks

32.32% upside

12 Months Forecast

Average 316.67 USD  32.32%

High 340 USD

Low 260 USD

Based on 16 Wall Street analysts offering 12 month price targets forPenumbra Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

16 ratings

12

Buy

4

Hold

0

Sell

Technical Score

By Trading Central

288.28 / 292.9394Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Bullish Evidence

Long Term

Weak Bullish Evidence

Sentiment

By Acuity

148 / 376 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Penumbra Inc

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.